General Toxicity Notes
Myelosuppressive and may aggravate uremic predisposition to hemorrhage and infection.
Excreted Unchanged %
None
Half-Life (Normalesrd) Hours
1.0-1.5/No data
Plasma Protein Binding %
75
Volume Of Distribution L/Kg
13-40
Dose For Normal Renal Function
3.7 mg/m2
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
100% [B]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
100% [B]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Dose for GFR 10-50, [D]
References
Owellen RJ, Hartke CA, Hains FO. Pharmacokinetics and metabolism of vinblastine in humans. Cancer Res. 1977; 37: 2597-602. [PMID: 889590] / Rahmani R, Zhou XJ. Pharmacokinetics and metabolism of vinca alkaloids. Cancer Surv. 1993; 17: 269-81. [PMID: 8137344]
Toxicity Notes
Vinca alkaloids may increase antidiuretic hormone secretion. Vd increases with time due to avid tissue binding.